Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, San Francisco
Age
25–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Female
2. ≥25 years of age at the time of study enrollment
3. Diagnosed with stage I-III invasive breast cancer or ductal carcinoma in situ, or determined to be high risk for primary breast cancer
4. If endocrine therapy was used, women must have completed at least 2 years of endocrine therapy as defined by either
1. Tamoxifen alone
2. Ovarian suppression plus tamoxifen or aromatase inhibitor
3. Ovarian suppression alone
5. Women must have been premenopausal at the time of endocrine therapy initiation. Premenopausal is defined as having had a menstrual cycle within 12 months before starting treatment.
6. For the biomarker assessments, patients must be off all endocrine therapy (tamoxifen, ovarian suppression with goserelin or leuprolide, or aromatase inhibitor) for at least 6 months prior to study enrollment.
7. For the biomarker assessments, patient must be off hormone contraceptives, fertility treatments, or other hormone therapies for at least 3 months prior to study enrollment
8. For the biomarker assessments, patient must have had regular periods the last 3 months.
You may not be if
1. Evidence for either local recurrence following use of adjuvant systemic therapy or evidence for distant recurrence of breast cancer.
2. Prior history of ovarian surgery or manipulation
3. Mother with premature ovarian failure as defined by onset of menopause at age \<40
4. Prior chemotherapy exposure
5. Prior history of endometriosis, anovulation or documented infertility
6. Pregnant at the time of study enrollment
Clareo Health | Investigating the Impact of Tamoxifen Therapy on Ovarian Aging
